Kevin S. Wilson Sells 1,631 Shares of Heska Corp (HSKA) Stock
Heska Corp (NASDAQ:HSKA) CEO Kevin S. Wilson sold 1,631 shares of the business’s stock in a transaction dated Friday, November 30th. The stock was sold at an average price of $104.00, for a total value of $169,624.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Shares of Heska stock opened at $102.77 on Thursday. The stock has a market capitalization of $779.95 million, a P/E ratio of 49.65 and a beta of 0.63. Heska Corp has a fifty-two week low of $56.59 and a fifty-two week high of $114.50.
Heska (NASDAQ:HSKA) last announced its quarterly earnings data on Tuesday, November 6th. The medical research company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.11. The firm had revenue of $30.96 million during the quarter, compared to analyst estimates of $31.14 million. Heska had a return on equity of 11.48% and a net margin of 1.01%. On average, equities analysts anticipate that Heska Corp will post 1.74 EPS for the current year.
A number of institutional investors have recently made changes to their positions in HSKA. Piedmont Investment Advisors LLC acquired a new position in shares of Heska during the second quarter worth approximately $162,000. SG Americas Securities LLC acquired a new position in shares of Heska during the second quarter worth approximately $191,000. Greenwood Capital Associates LLC acquired a new position in shares of Heska during the third quarter worth approximately $210,000. Virtu Financial LLC acquired a new position in shares of Heska during the third quarter worth approximately $223,000. Finally, Paloma Partners Management Co acquired a new stake in Heska in the second quarter worth approximately $228,000. 89.85% of the stock is owned by hedge funds and other institutional investors.
Heska Company Profile
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.
Recommended Story: What are the risks of holding treasury bonds?
Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.